Ontology type: schema:ScholarlyArticle
2021-02-18
AUTHORSSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, Maddalena Sansovini, Ilaria Grassi, Toni Ibrahim, Manuela Monti, Paola Caroli, Anna Sarnelli, Danila Diano, Valentina Di Iorio, Chiara Maria Grana, Corrado Cittanti, Federica Pieri, Stefano Severi, Giovanni Paganelli
ABSTRACTPurposeFDG-positive neuroendocrine tumors (NETs) have a poorer prognosis and exhibit shorter response duration to peptide receptor radionuclide therapy (PRRT). The aim of this prospective phase II study was to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE associated with metronomic capecitabine as a radiosensitizer agent in patients with advanced progressive FDG-positive gastro-entero-pancreatic (GEP) NETs.Patients and methodsPatients with advanced somatostatin receptor- and FDG-positive G1-G3 GEP-NETs (Ki67 < 55%) were treated with a cumulative activity of 27.5 GBq of 177Lu-DOTATATE divided in five cycles of 5.5 GBq each every 8 weeks. Capecitabine (1000–1500 mg daily) was administered orally in the inter-cycle period between 177Lu-DOTATATE treatments. Prior to commencing capecitabine, all patients were triaged with the dihydropyrimidine dehydrogenase (DPD) test. Only DPD-proficient individuals were enrolled. The primary objectives were disease control rate (DCR) and safety. Secondary aims included progression-free (PFS) and overall survival (OS). Treatment response was assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.ResultsFrom August 2015 to December 2016, 37 subjects were consecutively enrolled. A total of 25 (68%) were affected by pancreatic neuroendocrine tumors (P-NETs), and 12 (32%) had gastrointestinal neuroendocrine tumors (GI-NETs). By grading (WHO 2010 classification), 12 patients (32%) had G1 (Ki67 ≤ 2%), 22 (59%) had G2 (3% < Ki67 ≤ 20%), and 3 patients (9%) had G3 (Ki67 > 20%) NETs. Grade 3 (G3) or 4 (G4) hematological toxicity occurred in 16.2% of patients. Other G3-G4 adverse events were diarrhea in 5.4% of cases and asthenia in 5.4%. No renal toxicity was observed for the duration of follow-up. In 37 patients, 33 were evaluable for response. Objective responses included partial response (PR) in 10 patients (30%) and stable disease (SD) in 18 patients (55%), with a DCR of 85%. The median follow-up was 38 months (range 4.6–51.1 months). The median PFS was 31.4 months (17.6–45.4), and mOS was not reached.ConclusionsThis study demonstrated that the combination of PRRT with 177Lu-DOTATATE and metronomic capecitabine is active and well tolerated in patients with aggressive FDG-positive G1-G3 GEP-NETs. These data constitute the basis for a randomized study of PPRT alone vs. PRRT plus metronomic capecitabine. More... »
PAGES3260-3267
http://scigraph.springernature.com/pub.10.1007/s00259-021-05236-z
DOIhttp://dx.doi.org/10.1007/s00259-021-05236-z
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1135448627
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/33604690
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Capecitabine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Fluorodeoxyglucose F18",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neuroendocrine Tumors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Octreotide",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Organometallic Compounds",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pancreatic Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Positron Emission Tomography Computed Tomography",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prospective Studies",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Nicolini",
"givenName": "Silvia",
"id": "sg:person.01163253313.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163253313.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
"id": "http://www.grid.ac/institutes/grid.51462.34",
"name": [
"Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Bodei",
"givenName": "Lisa",
"id": "sg:person.01152500025.50",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152500025.50"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Bongiovanni",
"givenName": "Alberto",
"id": "sg:person.0650273700.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650273700.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Sansovini",
"givenName": "Maddalena",
"id": "sg:person.0773777325.99",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773777325.99"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Grassi",
"givenName": "Ilaria",
"id": "sg:person.0600503635.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600503635.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Ibrahim",
"givenName": "Toni",
"id": "sg:person.0620211740.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620211740.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Monti",
"givenName": "Manuela",
"id": "sg:person.01051423233.81",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051423233.81"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Caroli",
"givenName": "Paola",
"id": "sg:person.01231366513.57",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231366513.57"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Sarnelli",
"givenName": "Anna",
"id": "sg:person.01102322704.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102322704.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Diano",
"givenName": "Danila",
"id": "sg:person.01017401253.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017401253.25"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Di Iorio",
"givenName": "Valentina",
"id": "sg:person.01031773045.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031773045.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy",
"id": "http://www.grid.ac/institutes/grid.15667.33",
"name": [
"Division of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy"
],
"type": "Organization"
},
"familyName": "Grana",
"givenName": "Chiara Maria",
"id": "sg:person.01177774100.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177774100.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Unit, University of Ferrara, Ferrara, Italy",
"id": "http://www.grid.ac/institutes/grid.8484.0",
"name": [
"Nuclear Medicine Unit, University of Ferrara, Ferrara, Italy"
],
"type": "Organization"
},
"familyName": "Cittanti",
"givenName": "Corrado",
"id": "sg:person.0750042406.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750042406.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pathology Unit, Morgagni-Pierantoni Hospital, Forl\u00ec, Italy",
"id": "http://www.grid.ac/institutes/grid.415079.e",
"name": [
"Pathology Unit, Morgagni-Pierantoni Hospital, Forl\u00ec, Italy"
],
"type": "Organization"
},
"familyName": "Pieri",
"givenName": "Federica",
"id": "sg:person.0726705540.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726705540.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Severi",
"givenName": "Stefano",
"id": "sg:person.01252257737.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252257737.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy",
"id": "http://www.grid.ac/institutes/grid.419563.c",
"name": [
"Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy"
],
"type": "Organization"
},
"familyName": "Paganelli",
"givenName": "Giovanni",
"id": "sg:person.01042112525.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042112525.14"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s12094-007-0018-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025743688",
"https://doi.org/10.1007/s12094-007-0018-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-014-2893-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023409614",
"https://doi.org/10.1007/s00259-014-2893-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-010-1631-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028002113",
"https://doi.org/10.1007/s00259-010-1631-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-014-2735-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014772803",
"https://doi.org/10.1007/s00259-014-2735-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-012-2149-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020792955",
"https://doi.org/10.1007/s00259-012-2149-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-014-2906-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026573462",
"https://doi.org/10.1007/s00259-014-2906-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-013-2369-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013282064",
"https://doi.org/10.1007/s00259-013-2369-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-011-1902-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019962478",
"https://doi.org/10.1007/s00259-011-1902-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-016-3533-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024004526",
"https://doi.org/10.1007/s00259-016-3533-z"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-02-18",
"datePublishedReg": "2021-02-18",
"description": "PurposeFDG-positive neuroendocrine tumors (NETs) have a poorer prognosis and exhibit shorter response duration to peptide receptor radionuclide therapy (PRRT). The aim of this prospective phase II study was to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE associated with metronomic capecitabine as a radiosensitizer agent in patients with advanced progressive FDG-positive gastro-entero-pancreatic (GEP) NETs.Patients and methodsPatients with advanced somatostatin receptor- and FDG-positive G1-G3 GEP-NETs (Ki67\u2009<\u200955%) were treated with a cumulative activity of 27.5\u00a0GBq of 177Lu-DOTATATE divided in five cycles of 5.5\u00a0GBq each every 8\u00a0weeks. Capecitabine (1000\u20131500\u00a0mg daily) was administered orally in the inter-cycle period between 177Lu-DOTATATE treatments. Prior to commencing capecitabine, all patients were triaged with the dihydropyrimidine dehydrogenase (DPD) test. Only DPD-proficient individuals were enrolled. The primary objectives were disease control rate (DCR) and safety. Secondary aims included progression-free (PFS) and overall survival (OS). Treatment response was assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.ResultsFrom August 2015 to December 2016, 37 subjects were consecutively enrolled. A total of 25 (68%) were affected by pancreatic neuroendocrine tumors (P-NETs), and 12 (32%) had gastrointestinal neuroendocrine tumors (GI-NETs). By grading (WHO 2010 classification), 12 patients (32%) had G1 (Ki67\u2009\u2264\u20092%), 22 (59%) had G2 (3%\u2009<\u2009Ki67\u2009\u2264\u200920%), and 3 patients (9%) had G3 (Ki67\u2009>\u200920%) NETs. Grade 3 (G3) or 4 (G4) hematological toxicity occurred in 16.2% of patients. Other G3-G4 adverse events were diarrhea in 5.4% of cases and asthenia in 5.4%. No renal toxicity was observed for the duration of follow-up. In 37 patients, 33 were evaluable for response. Objective responses included partial response (PR) in 10 patients (30%) and stable disease (SD) in 18 patients (55%), with a DCR of 85%. The median follow-up was 38\u00a0months (range 4.6\u201351.1\u00a0months). The median PFS was 31.4\u00a0months (17.6\u201345.4), and mOS was not reached.ConclusionsThis study demonstrated that the combination of PRRT with 177Lu-DOTATATE and metronomic capecitabine is active and well tolerated in patients with aggressive FDG-positive G1-G3 GEP-NETs. These data constitute the basis for a randomized study of PPRT alone vs. PRRT plus metronomic capecitabine.",
"genre": "article",
"id": "sg:pub.10.1007/s00259-021-05236-z",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1297401",
"issn": [
"1619-7070",
"1619-7089"
],
"name": "European Journal of Nuclear Medicine and Molecular Imaging",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "10",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "48"
}
],
"keywords": [
"disease control rate",
"metronomic capecitabine",
"neuroendocrine tumors",
"stable disease",
"overall survival",
"partial response",
"gastro-entero-pancreatic neuroendocrine tumors",
"prospective phase II study",
"phase II study",
"Common Terminology Criteria",
"Response Evaluation Criteria",
"receptor radionuclide therapy",
"gastrointestinal neuroendocrine tumors",
"pancreatic neuroendocrine tumors",
"shorter response duration",
"Terminology Criteria",
"median PFS",
"II study",
"hematological toxicity",
"adverse events",
"objective response",
"randomized study",
"poor prognosis",
"renal toxicity",
"GEP-NETs",
"control rate",
"somatostatin receptors",
"treatment response",
"grade 3",
"capecitabine",
"response duration",
"patients",
"radionuclide therapy",
"solid tumors",
"secondary aim",
"tumors",
"radiosensitizer agent",
"ConclusionsThis study",
"cumulative activity",
"version 1.1",
"PRRT",
"toxicity",
"months",
"primary objective",
"dehydrogenase test",
"duration",
"GBq",
"response",
"MethodsPatients",
"combined use",
"asthenia",
"diarrhea",
"prognosis",
"aim",
"PFS",
"therapy",
"gastro",
"G1",
"disease",
"weeks",
"receptors",
"study",
"efficacy",
"survival",
"treatment",
"total",
"criteria",
"PPRT",
"subjects",
"safety",
"evaluation criteria",
"agents",
"individuals",
"G2",
"period",
"activity",
"cases",
"rate",
"events",
"test",
"objective",
"use",
"combination",
"data",
"cycle",
"basis",
"GEP",
"MOS"
],
"name": "Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors",
"pagination": "3260-3267",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1135448627"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00259-021-05236-z"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"33604690"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00259-021-05236-z",
"https://app.dimensions.ai/details/publication/pub.1135448627"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:24",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_904.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00259-021-05236-z"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-021-05236-z'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-021-05236-z'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-021-05236-z'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-021-05236-z'
This table displays all metadata directly associated to this object as RDF triples.
349 TRIPLES
22 PREDICATES
132 URIs
115 LITERALS
16 BLANK NODES